SCHEMBL311671

SCHEMBL311671

O=c1cc(-c2ccc(O)cc2)oc2ncnc(O)c12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.52
KDM4E B2RXH2 5/20 0.52
MAPT P10636 4/20 0.52
TDP1 Q9NUW8 4/20 0.52
PKM P14618 3/20 0.52
APEX1 P27695 2/20 0.52
POLB P06746 2/20 0.52
INPPL1 O15357 1/20 0.52
ALPL P05186 1/20 0.52
ALPI P09923 1/20 0.52
GAA P10253 1/20 0.52
ALPG P10696 1/20 0.52
RECQL P46063 1/20 0.52
BLM P54132 1/20 0.52
MCL1 Q07820 1/20 0.52
PFKFB3 Q16875 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
CYP3A4 P08684 5/20 0.51
HPGD P15428 4/20 0.51
NPC1 O15118 4/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL311892 0.79 KMT2A (0.58) KMT2AKDM4EMAPTTDP1PKM
SCHEMBL311484 0.78 MAPT (0.60) KMT2AKDM4EMAPTTDP1PKM
SCHEMBL311737 0.77 TDP1 (0.52) KMT2AKDM4EMAPTTDP1PKM
SCHEMBL312039 0.75 CYP3A4 (0.52) KMT2AKDM4EMAPTTDP1PKM
SCHEMBL311589 0.73 CYP3A4 (0.49) KMT2AKDM4EMAPTTDP1PKM
SCHEMBL312751 0.72 MAPT (0.59) KMT2AKDM4EMAPTTDP1PKM
SCHEMBL29636735 0.71 LCK (0.78) KMT2AKDM4EMAPTTDP1PKM
SCHEMBL311324 0.71 NPC1 (0.60) KMT2AKDM4EMAPTTDP1PKM
SCHEMBL312658 0.70 CYP3A4 (0.46) KMT2AKDM4EMAPTTDP1PKM
SCHEMBL311672 0.70 CYP3A4 (0.46) KMT2AKDM4EMAPTTDP1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242130-B2 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2012-08-14 US disclosed
EP-1838296-B1 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP (CA) 2012-08-08 EP disclosed
US-8093273-B2 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2012-01-10 US disclosed
EP-2332527-A2 Flavanoids and Isoflavanoids for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2011-06-15 EP disclosed
US-20090259048-A1 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP. (CA) 2009-10-15 US disclosed
EP-1838296-A2 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP. (CA) 2007-10-03 EP disclosed
US-20060205767-A1 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases HEPALINK (HONG KONG) LIMITED (HK) 2006-09-14 US disclosed
WO-2006045096-A2 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP. (CA) 2006-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060205767-A1 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases APOB, APOL1, FABP3 KMT2A 2842/4885KDM4E 3504/4885MAPT 2914/4885
US-20090259048-A1 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES APOB, APOL1, FABP3 KMT2A 2842/4885KDM4E 3504/4885MAPT 2914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.